Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pamrevlumab · FG-3019

Monoclonal antibody · Inhibitor of connective tissue growth factor (CCN2) · developed by Kyntra Bio

Phase 3 Most advanced trial (none active)
KYNB Developer
3 Registered trials

What is Pamrevlumab?

Pamrevlumab is a human monoclonal antibody that binds connective tissue growth factor (CTGF), preventing its binding to its receptor and subsequent receptor activation. It is studied in unresectable pancreatic cancer and idiopathic pulmonary fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FG-3019
Drug type
Monoclonal antibody
Targets
connective tissue growth factor (CCN2)
Mechanism
Inhibitor of connective tissue growth factor (CCN2)
Pathways
ligand-receptor binding and receptor activation, collagen and fibronectin production, cell proliferation, migration and adhesion, angiogenesis
Therapy area
Oncology, Respiratory
Developer
Kyntra Bio (KYNB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
QS5F6VTS0O

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03955146 Phase 3 Idiopathic Pulmonary Fibrosis Terminated KYNB
NCT03941093 Phase 3 Pancreatic Cancer Non-resectable Completed KYNB
NCT02210559 Phase 1/2 Pancreatic Cancer (Unresectable) Completed KYNB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Pulmonary FibrosisPancreatic Cancer (Unresectable)Pancreatic Cancer Non-resectable

More from Kyntra Bio

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KYNB page.

Follow KYNB, the company behind Pamrevlumab

See KYNB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KYNB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.